Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Tyra Biosciences Inc TYRA

Tyra Biosciences, Inc. is a clinical-stage biotechnology company. It is focused on developing precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. Its in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations to cause acquired resistance to... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >

Current News (NDAQ:TYRA)

Tyra Biosciences to Present at Upcoming Investor Conferences

PR Newswire November 13, 2024

Tyra Biosciences Reports Third Quarter 2024 Financial Results and Highlights

PR Newswire November 7, 2024

Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301)

PR Newswire October 28, 2024

Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC)

PR Newswire October 24, 2024

Tyra Biosciences to Host Conference Call on Interim Clinical Data of TYRA-300 from SURF301 Phase 1/2 Study on October 25, 2024, at 8am ET

PR Newswire October 23, 2024

Tyra Biosciences Announces Late-Breaking Oral Presentation on Preliminary Safety and Anti-Tumor Activity of TYRA-300 from SURF301 at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2024)

PR Newswire October 11, 2024

The Schall Law Firm Is Looking Into Tyra Biosciences Inc For Possibly Violating Securities Laws And The Firm Seeks Shareholder Participation

Accesswire September 12, 2024

Tyra Biosciences to Present at the 2024 Cantor Global Healthcare Conference

PR Newswire September 11, 2024

Tyra Biosciences, Inc. May Have Defrauded Shareholders And Impacted Individuals Are Invited To Join The Schall Law Firm's Investigation

Accesswire September 11, 2024

Opinion & Analysis (NDAQ:TYRA)

No current opinion is available.

Bullboard Posts (NDAQ:TYRA)

US Companies Moving the Markets, Evening edition <br>Fri, Fe

NEWS: $TYRA US Companies Moving the Markets, Evening edition Fri, Feb 02, 2024 as of 4:00 pm ETA look at the top 10 most actives in the...
whytestocks - February 2, 2024

S&P 500 Gains Over 1%; Amazon Earnings Top Expectations | Be

Just In: $TYRA S&P 500 Gains Over 1%; Amazon Earnings Top Expectations | BenzingaU.S. stocks traded higher toward the end of trading...
whytestocks - February 2, 2024